Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges
Sumira Malik,
Shristi Kishore,
Sagnik Nag,
Archna Dhasmana,
Subham Preetam,
Oishi Mitra,
Darwin A. León-Figueroa,
Aroop Mohanty,
Vijay Kumar Chattu,
Marjan Assefi,
Bijaya K. Padhi,
Ranjit Sah
Affiliations
Sumira Malik
Amity Institute of Biotechnology, Amity University Jharkhand, Ranchi 834001, Jharkhand, India
Shristi Kishore
Amity Institute of Biotechnology, Amity University Jharkhand, Ranchi 834001, Jharkhand, India
Sagnik Nag
Department of Biotechnology, School of Biosciences & Technology, Vellore Institute of Technology (VIT), Tiruvalam Road, Vellore 632014, Tamil Nadu, India
Archna Dhasmana
Himalayan School of Biosciences, Swami Rama Himalayan University, Jolly Grant, Dehradun 248140, Uttarakhand, India
Subham Preetam
Institute of Advanced Materials, IAAM, Gammalkilsvägen 18, 59053 Ulrika, Sweden
Oishi Mitra
Department of Biotechnology, School of Biosciences & Technology, Vellore Institute of Technology (VIT), Tiruvalam Road, Vellore 632014, Tamil Nadu, India
Darwin A. León-Figueroa
Facultad de Medicina Humana, Universidad de San Martín de Porres, Chiclayo 15011, Peru
Aroop Mohanty
Department of Microbiology, All India Institute of Medical Sciences, Gorakhpur 273008, Uttar Pradesh, India
Vijay Kumar Chattu
Department of Occupational Science & Occupational Therapy, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada
Marjan Assefi
Joint School of NanoScience and Nano Engineering, University of North Carolina, Greensboro, NC 27402-6170, USA
Bijaya K. Padhi
Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, Punjab, India
Ranjit Sah
Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal
The global outgoing outbreaks of Ebola virus disease (EVD) in different regions of Sudan, Uganda, and Western Africa have brought into focus the inadequacies and restrictions of pre-designed vaccines for use in the battle against EVD, which has affirmed the urgent need for the development of a systematic protocol to produce Ebola vaccines prior to an outbreak. There are several vaccines available being developed by preclinical trials and human-based clinical trials. The group of vaccines includes virus-like particle-based vaccines, DNA-based vaccines, whole virus recombinant vaccines, incompetent replication originated vaccines, and competent replication vaccines. The limitations and challenges faced in the development of Ebola vaccines are the selection of immunogenic, rapid-responsive, cross-protective immunity-based vaccinations with assurances of prolonged protection. Another issue for the manufacturing and distribution of vaccines involves post authorization, licensing, and surveillance to ensure a vaccine’s efficacy towards combating the Ebola outbreak. The current review focuses on the development process, the current perspective on the development of an Ebola vaccine, and future challenges for combatting future emerging Ebola infectious disease.